نتایج جستجو برای: lanthanum silicate
تعداد نتایج: 13926 فیلتر نتایج به سال:
BACKGROUND High levels of circulating fibroblast growth factor 23 (FGF23) are associated with chronic kidney disease (CKD) progression and high mortality. In the Phosphate Reduction Evaluation of FGF23 in Early CKD Treatment (PREFECT) study, we assessed the effect of reducing intestinal phosphate absorption using lanthanum carbonate on FGF23 levels in normophosphatemic patients with CKD stage 3...
...................................................................................................................... iii
La(21)Ru(9+x)In(5-x) (Pearson symbol tI140) is isotypic to the filled Y(3)Rh(2)-type structure, from which it can be derived through an ordered substitution at two sites. One of the square-prismatic sites (site symmetry ..m) is occupied by a mixture of Ru and In atoms and one of the square-antiprismatic sites (4/m..) is fully occupied by In atoms.
[La[N(SiHMe2)2]2[CH(PPh2NSiMe3)2]], which was obtained via an amine elimination starting from [CH2(PPh2NSiMe3)2] and [La[N(SiHMe2)2]3(THF)2], was used as catalyst for the hydroamination/cyclisation, the hydrosilylation and the sequential hydroamination/hydrosilylation reaction.
BACKGROUND AND OBJECTIVES Management of hyperphosphatemia, a predictor of mortality in chronic kidney disease, is challenging. Nonadherence to dietary phosphate binders, in part, contributes to uncontrolled serum phosphorus levels. This phase IIIb trial assessed the efficacy of increased dosages (3000 to 4500 mg/d) of reformulated lanthanum carbonate (500-, 750-, and 1000-mg tablets) in nonresp...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید